On May 14, 2025, the Food and Drug Administration granted accelerated approval for telisotuzumab vedotin-tllv (Emrelis, AbbVie Inc.), a c-Met-targeted antibody and microtubule inhibitor conjugate, for...
On May 14, 2025, the Food and Drug Administration sanctioned belzutifan (Welireg, Merck & Co., Inc.) for adult and pediatric patients aged 12 and older diagnosed with locally advanced, unresectabl...
On May 8, 2025, the Food and Drug Administration approved the use of avutometinib and defactinib (Avmapki Fakzynja Co-pack, Verastem, Inc.) for adults with KRAS-mutated recurrent low-grade serous ovar...
Gliomas IntroductionBrain gliomas, especially aggressive types such as glioblastoma multiforme (GBM), have long been extremely challenging to treat because of their insensitivity to traditional therap...
Medical Tourism in China in 2025 China has emerged as a leading destination for medical tourism, offering world-class hospitals, affordable treatments, and cutting-edge procedures. From cosmetic su...
Introduction Chimeric Antigen Receptor (CAR) T-cell therapy has already transformed the landscape of cancer treatment. Now, the 4th generation CAR T-cell therapy, augmented with interleukin-15 (IL-15...
Best Cancer Hospitals in China China has become a world leader in medical innovation, especially in oncology. The nation has, over the past decade, made tremendous progress in biotechnology, fo...
On November 8, 2024, the Food and Drug Administration sanctioned obecabtagene autoleucel (Aucatzyl, Autolus Inc.), a CD19-targeted genetically engineered autologous CAR T cell therapy, for people with...
IntroductionHematological malignancies, such as leukemias, lymphomas, and multiple myeloma, are a heterogeneous group of cancers that arise in the bone marrow and lymphatic system. Conventional trea...
CAR T Cell therapyChimeric Antigen Receptor (CAR) T-cell therapy is a revolutionary therapeutic strategy in hematologic malignancy treatment, recording high remission rates in therapy-refractory cas...